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Summary 
Boswellia species (Burseraceae) are trees or shrubs whose area of distribution covers the 
wide geographic area between North Africa and India. After incision, their bark produces oleo-
gum resin known as frankincense (Olibanum). In traditional medicine, frankincense is often used 
for medical treatment of arthritis, asthma, ulcerative colitis, coughs, sores, and wound healing. 
Various frankincense preparations are marketed almost exclusively as dietary supplements. 
Indian frankincense, or Olibanum indicum, is official in the European Pharmacopoeia. 
The major components of frankincense are boswellic acids, among which the most 
important and abundant is 3-O-acetyl-11-keto-β-boswellic acid (AKBA). AKBA is a                              
5-lipoxygenase inhibitor with anti-inflammatory and anti-arthritic effects. Besides, frankincense 
contains essential oil, whose composition greatly depends on the biological source, as well as 
arabinogalactans and glycoproteins. 
In small clinical trials, certain benefits of various frankincense preparations have been 
demonstrated in cases of ulcerative colitis, bronchial asthma, mild symptoms of irritable bowel 
syndrome, and various disorders of osteo-muscular system. However, for collagenous colitis and 
Crohn’s disease remission maintenance, the evidence is ambiguous or negative. AKBA-
containing extract was found advantageous in patients with osteoarthritis, and to some extent with 
rheumatoid arthritis. Almost all the trials had serious flaws in experimental design, such as 
insufficient sample size and/or incomplete reporting of data. For any clinical recommendation of 
frankincense preparations, larger and better-designed studies are needed. 
 







Frankincense, Gummi Boswellii or Olibanum, is an oleo-gum resin whose 
biological source are as many as 24 plant species (out of 25) belonging to the genus 
Boswellia (family Burseraceae). Representatives of this genus are distributed across the 
huge geographic area between the tropical regions of Africa and arid forests of Punjab 
and West Bengal in India (1-4). Oleo-gum resin of one of the most important and best-
known species of this genus, B. sacra, was brought to the eastern Mediterranean by the 
so-called “incense trade route” - the oldest caravan route in the world, which included a 
network of ancient land and sea trading routes linking the Mediterranean empires with 
the southern and eastern sources of fragrant substances, spices, and luxury goods (1,4). It 
stretched from Mediterranean ports across the Levant and Egypt through North Africa to 
Yemen and Oman in the Arabian Peninsula, as well as to India and even beyond. The 
frankincense trade flourished between the 3rd century BC and the 2nd century AD (5). 
Frankincense is most often produced by incising the bark of B. serrata Roxb. ex 
Colebr. from India, B. sacra Flueck. (syn. B. carterii Birdw.), which grows in the Middle 
East and the Arabian Peninsula, B. frereana Birdw. from the region of Northeast Africa 
(Somalia and Ethiopia), B. papyrifera (Caill. ex Delile) Hochst. and B. rivae Engl. 
(Ethiopia), as well as B. neglecta S. Moore (Eritrea) (6).  
The milky exudate that drips out of the incision is whitish in the beginning and 
gradually hardens in contact with air, changing its color as well. It is collected throughout 
the year and marketed, fresh or dried, in the form of fragrant, small, ovoid pieces similar 
to drops, reddish-brown, greenish-yellow, dull yellow or yellow-orange in color. Pieces 
of oleo-gum resin are sometimes agglomerated into chunks up to 5 cm long and up to       
2 cm thick. The fracture is smooth, waxy and translucent. It burns readily and emits an 
agreeable characteristic balsamic resinous odor. Most of the frankincense in trade comes 
from Oman, Yemen, and Somalia (7,8). 
Chemical Composition 
Frankincense contains 5-9% of essential oil, whose composition varies in relation 
to the biological source, 65-85% of alcohol-soluble resin and about 20% of water-soluble 
gum (a mixture of heteropolysaccharides, polysaccharides and polymeric substances) (9). 
Essential oil 
Essential oil obtained by distillation of B. sacra oleo-gum resin is the most 
investigated so far. It appears as pale yellowish, fragrant oil lighter than water, whose 
principal constituent (up to 60%) is identified as octyl acetate. The others are, in order of 
descending quantities, 1-octanol (11.9%), α-pinene (10.9%), verticilla-4(20),7,11-triene 
(6.0%), incensol acetate (2-3%), bornyl acetate (2.2%), cembrene A (2.1%), linalool 
(2.1%), α-thujene (1.7%), E-β-ocimene (1.7%), limonene (1.5%), p-cymene (1.4%),                  




(0.7%), myrcene (0.5%), α-pinene epoxyde (0.5%), Z-β-ocimene (0.4%), trans-verbenol 
(0.4%), terpinene-4-ol (0.4%), geranyl acetate (0.4%), hexyl acetate (0.3%), E-nerolidol 
(0.2%) and cembrene C (0.1%) (7,9).  
The most abundant compound of essential oil of B. serrata oleo-gum resin is α-
pinene (up to 45%). Its distillate is a colourless oil with a significant share of α-thujene 
(12%), along with methylchavicol (11.6%), myrcene (3.8%), sabinene (2.2%), 
methyleugenol (2.1%), germacrene D (2.0%), cembrenol (1.9%), limonene (1.9%),                      
α-phellandrene (1%), p-cymene (1%), linalool (0.9%), kessane (0.9%), β-pinene (0.7%), 
perillene (0.5%) and cembrene A (0.5%) (7,9). 
Resin 
The main constituents of frankincense resinous fraction are triterpenoid boswellic 
acids (more than 12 compounds), among which the most important are 11-keto-β-
boswellic acid (KBA), 3-O-acetyl-11-keto-β-boswellic acid (AKBA), α- and β-boswellic 
acid (α- and β-BA) and their acetyl derivatives (3-O-acetyl-α-boswellic acid and 3-O-
acetyl-β-boswellic acid) (Figure 1). Crude oleo-gum resin typically contains up to 30% 
boswellic acids in total, while ethanol extract of frankincense contains up to 43% 
boswellic acids (7,9). 
 
 
Figure 1. Boswellic acids 





Heteropolysaccharides, polysaccharides and polymeric substances 
Major constituents (32-56%) of this fraction, obtained from B. sacra and B. serrata 
oleo-gum resin, are arabinogalactans, whose molecular backbone mainly consists of                    
D-galactose units (~ 60 mol%), with branching through positions 3 and 6. Side chains are 
composed mostly of glucuronic acid (~ 9 mol%) and arabinose (2-14 mol%), with                           
4-O-methyl-glucuronic acid (13-26 mol%) as the terminal molecule (7,9).  
Beside arabinogalactans, frankincense contains glucoproteins, whose carbohydrate 
part almost entirely consist of L-arabinose (~ 90 mol%) and D-galactose (8 mol%). 
Arabinose units have been found to make 1,2 and, in smaller amounts, 1,3 bonds and form 
chains with a high content of terminal arabinose units. On the other hand, the protein part 
of the glucoprotein molecule contains high share of hydroxyproline (~ 50 mol%) and 
serine (~ 20 mol%). It should be underlined that B. serrata gum is richer in proteins (22%) 
than B. carterii (6%). (9) 
Traditional use 
Throughout the long history of its use, frankincense has been most commonly used 
in religious rituals, by incineration and inhalation of its white, fragrant smoke, with the 
aim of improving emotional well-being and achieving “higher levels of spirituality and 
improving mental perception, meditation, prayer and awareness” (1-4). 
The oleo-gum resin of both B. sacra and B. serrata, as the most important biological 
sources of frankincense, has been used in cosmetics since ancient times. A black pigment 
kohl was made from carbonized frankincense and used by Egyptian women as paint for 
their eyelids; also in eye washes, for soothing sore eyes, etc. The oleo-gum resin of B. 
sacra has also been used to reinvigorate the skin, to make hair-removal preparations, and 
in formulation of various fragrances for personal care. Even in modern times, some lines 
of skin care and cosmetic products contain frankincense for treatment of different skin 
imperfections (1,3). 
Medieval Persian physician and polymath Ibn Sina (Avicenna, 980-1037 AD) 
recommended the use of frankincense for dysentery, fever, tumors, ulcers and vomiting. 
Information on the use of frankincense as digestive, purgative, diuretic, for teeth and gum 
support, to enhance memory and to alleviate emotional and psychological problems, also 
came from the Middle East and spread worldwide (3). 
B. serrata oleo-gum resin has been used in Ayurveda and Unani medical systems 
in India against a whole array of health disorders, such as diarrhea, dysentery, ringworm 
infestations, boils, fever (as an antipyretic), skin, blood and cardiovascular diseases, 
inflammations of the esophagus, larynx and oral cavity mucosa, as well as with claims of 
benefit in respiratory ailments (bronchitis, asthma, cough), irregular vaginal secretion and 
menstrual cycle, loss of hair, jaundice, hemorrhoids, syphilis, and liver ailments. It has 
also been used as a diaphoretic, astringent, diuretic and both as an internal and external 




promote blood circulation, relax muscles, and mitigate discomfort in menstrual disorders, 
as well as against pain. Listed in ancient medical compendia as ru xiang, it is also used 
externally to reduce swelling in lesions and to promote wound healing (3). In Africa, 
frankincense is largely recommended by herbalists as a tonic, diuretic, as well as against 
syphilis and bilharzia (schistosomiasis) (3). 
Modern use of frankincense 
For pre-marketing authorization and product licensing purposes, Canadian Natural 
Health Products Directorate (NHPD) has published three monographs that define the 
conditions for oromucosal, oral, and topical use of frankincense and/or its preparations. 
According to the NHPD, oral administration of dried Boswellia oleo-gum resin is 
permitted as an astringent, diuretic, to relieve nervous tension; in TCM, to improve the 
life energy (qi) flow, to alleviate urinary disorders, and to eliminate damp wind. The 
allowed indications for topical use in TCM are the treatment of carbuncles, improvement 
of tissue regeneration, treatment of injuries, alleviation of problems with the gums, teeth, 
oral cavity and throat, as well as the alleviation of pain, promotion of sore healing, and 
reduction of swelling (3). 
Frankincense in contemporary pharmacopoeias  
B. serrata oleo-gum resin and extract have been official in the United States 
Pharmacopoeia since December 1st, 2010, when corresponding monographs were 
published in the 2nd Supplement to the United States Pharmacopeia, 33rd Revision – 
National Formulary 28th edition (USP 33 NF 28) (3). For Indian frankincense (Olibanum 
indicum), an official monograph was published in the European Pharmacopoeia 8.0 (Ph. 
Eur. 8.0), where this substance is described as “Air-dried gum-resin exudate, obtained by 
incision in the stem or branches of Boswellia serrata Roxb. ex Colebr.” (11). 
Use of frankincense in food and cosmetic industry 
The essential oil, obtained by hydrodistillation from the oleo-gum resin of B. 
carterii and other Boswellia species (referred to as “Olibanum Oil”), has been regulated 
as a food additive in the USA since June 2010 (Food Chemicals Codex) and permitted 
for direct addition to food for human consumption (3).  It is used in the food industry as 
an additive to meat products, various beverages (both alcoholic and non-alcoholic), 
pastries, frozen dairy products, etc. Frankincense extract and oil are also used in the 
cosmetic industry as fragrance fixatives or scent ingredients, in personal care products 




Frankincense in the treatment of peritumoral oedema derived from brain 
tumours 
An orphan designation (EU/3/02/117; 2002) was granted by the European 
Commission to Pharmasan GmbH (Freiburg, Germany) for B. serrata resin extract for 
the treatment of peritumoral oedema derived from brain tumours (13).  
Uncontrollable tumour growth in brain tissues causes an abnormal build-up of 
fluids, with consequent swelling of the peritumoral tissues (peritumoral oedema). It 
causes an increase in intracranial pressure, which leads to brain compression and 
manifestation of symptoms related to the dysfunction of the affected regions. Peritumoral 
oedema is life-threatening, so therapy is obligatory (13). Glucocorticoids were authorised 
as the drugs of choice for the treatment of peritumoral oedema in the European 
Community in 2002. Although useful for long-term treatment, glucocorticoids are 
notorious for their serious side effects. B. serrata resin extract might offer a better safety 
profile than glucocorticoids. It blocks the biosynthesis of leukotrienes, which participate 
in the regulation of the state of blood vessels and lower respiratory passageways, and also 
affects the activity of white blood cells. Leukotrienes seem to contribute to the 
development of peritumoral oedema in the brain (13).  However, on request of the 
sponsor, this product was withdrawn from the Community Register of Orphan Medicinal 
Products in November 2006 (13). 
Pharmacology 
Analgesic Activity 
It has been shown that intraperitoneal gavage of the non-phenolic fraction of the 
crude B. serrata oleo-gum resin induced analgesia in 60% of male albino rats (Haffkine 
strain) weighing between 125 and 200 g at a dose of 60 mg/kg body weight (b.w.). At a 
dose of 150 mg/kg b.w., analgesia has been observed in 70% of rats, as well as a 70% 
reduction of spontaneous motoric activity, which lasted for 2 h. The analgetic effect has 
been found to be proportionate to the activity of 3–4.5 mg/kg b.w. of morphine. Both the 
sedative and analgesic effects of the non-polar fraction of B. serrata oleo-gum resin were 
antagonized by the treatment of the animals with sub-analgesic dose of morphine 
hydrochloride (7,14). 
The analgesic effect in rats was tested by both the hot-wire and mechanical 
compression methods. The non-phenolic fraction was produced by distillation of the B. 
serrata oleo-gum resin; the obtained oil was dissolved in diethyl ether and the phenolic 
fraction was separated by liquid-liquid extraction with aqueous sodium hydroxide. The 
ethereal layer (containing the non-phenolic fraction) was successively washed to remove 
traces of alkaline agents, and the solvent was removed under reduced pressure. The 
phenolic fraction was separated from the aqueous layer after neutralization with 




solution were suspended in Polysorbate-80 and administered intraperitoneally to 
laboratory animals (14). 
Anticomplementary activity 
Anticomplementary activity of boswellic acids has been assessed in vitro via the 
decrease of immune-induced haemolysis of opsonized sheep erythrocytes by pooled 
guinea-pig serum. Boswellic acids inhibit the C3-convertase enzyme, which is necessary 
for the activation of the classical complement pathway, with a threshold of 100 μg/ ml 
(15).  
Like the other triterpenic acids of plant origin (i.e. glycyrrhetic, ursolic, oleanolic 
and crataegolic), β-boswellic acid expressed a prominent inhibitory activity for both the 
classical and the alternative complement pathway. At concentrations of between 0.005–
0.1 mM, a significant decrease of immunohemolysis has been observed in vitro, with an 
IC50 value of 10 μmol/L. (16) 
Anti-inflammatory activity 
In vivo assessment of the anti-inflammatory activity of aqueous extract of crude 
frankincense showed a significant inhibition of both maximal and total oedema response 
during the span of 6 hours of carrageenan-induced rat paw oedema (7). At 50.0–200.0 
mg/kg b.w. of oleo-gum resin or aqueous-methanol extract of the gum (9:1), intragastric 
gavage diminished carrageenan- or adjuvant- (Mycobacterium butyricum suspended in 
mineral oil) induced paw oedema in rats by 34 –73% (7). At the same dose, an ethanol 
extract of crude frankincense showed a prominent anti-inflammatory activity in 
carrageenan-induced oedema in rats and mice, and dextran-induced oedema in rats. A 
significant antiarthritic activity of the investigated extract was observed; however, it was 
found ineffective in the case of cotton pellet-induced granuloma test. Finally, the 
treatment inhibited an increase in serum transaminase levels induced by inflammation, as 
well as leukocyte counts, but did not show antipyretic or analgesic activity in rats (7).  
In vivo anti-inflammatory activity of crude frankincense and isolated boswellic 
acids was investigated in laboratory animals (rats) with adjuvant-induced arthritis. The 
animals were treated with 100.0 mg/kg b.w. of the crude drug preparation or 200.0 mg/kg 
b.w. of boswellic acids, applied by intragastric gavage for 2 weeks (7). The activity of β-
glucuronidase was measured to estimate the lysosomes stability. This investigation 
showed that the treatment of laboratory animals with either the extract or boswellic acid 
increased lysosomal stability and exerted a protective effect on the integrity of lysosomes. 
Boswellic acids specifically inhibit the activity of elastase in leukocytes, as well as the 
proliferation and activity of topoisomerases of leukaemia and glioma cell lines, leading 
to apoptosis (7). 
Methanol extract of crude frankincense, applied topically, markedly inhibited                  




proliferation, the number of epidermal cell layers and tumour development induced by 
7,12-dimethylbenz[a]anthracene in mice. The addition of the crude drug (0.2%; 10-24 
weeks) to the diet of CF-1 mice, reduced the growth of parametrial fat pad weight and 
inhibited azoxymethane-induced formation of aberrant crypt foci (ACF) of 
morphological changes observed in rodents after the administration of colon-specific 
carcinogens, such as azoxymethane, by 46% (7). 
Mechanisms of Action 
It is assumed that boswellic acids in general, and 3-O-acetyl-11-keto-β-boswellic 
acid (AKBA) in particular, as the most important component of frankincense, contribute 
the most to the pharmacological activities of this herbal substance. AKBA is involved in 
the regulation of numerous cellular signaling pathways that initiate various inflammatory 
diseases and types of tumours; therefore, it is a natural product that is considered 
potentially useful for the treatment of a large number of diseases, such as arthritis, 
Crohn’s disease, irritable bowel syndrome, psoriasis, glioma, colon cancer, leukaemia, 
prostate cancer, as a substitute to nonsteroidal anti-inflammatory drugs (NSAIDs).                      
In vitro and animal studies showed that the anti-inflammatory activity of AKBA occurs 
mainly through inhibition of 5-lipoxygenase (5-LOX) and, to a lesser extent, 
cyclooxygenase-1 (COX-1). It also inhibits nuclear transcription factor NF-κB, 
significantly reducing the biosynthesis of a key proinflammatory cytokine, tumour 
necrosis factor α (TNF-α) (8,10,12,17). 
Inhibition of 5-lipoxygenase 
Investigations on the anti-inflammatory activity of boswellic acids in the light of         
5-lipoxygenase (5-LOX) inhibition in laboratory animal models and in vitro, showed that 
AKBA is particularly active, in a dose-dependent manner. 5-LOX is an enzyme with 
crucial position in the biosynthesis of proinflammatory products such as                            
5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4 (LTB4), which are 
responsible for chemotaxis, bronchoconstriction, and increased vascular permeability. 
The inhibition of 5-LOX strengthens the hypothesis that AKBA could influence the 
course of all inflammatory diseases with 5-LOX pathogenesis. The other anti-
inflammatory ingredients of plants, such as quercetin and similar compounds, also inhibit 
this enzyme, but more generally, as antioxidants, while boswellic acids appear to act like 
specific inhibitors of 5-LOX (2,7,17). 
Inhibition of human leukocyte elastase 
Levels of 5-LOX and human leukocyte elastase (HLE) increase together in many 
inflammatory diseases. In vitro, AKBA blocks the HLE activity in a dose-dependent 
manner, in contrast to the other inhibitors of leukotriene biosynthesis. AKBA exerts a 
non-competitive mode of HLE blocking, which is a unique feature of this natural product. 




secretion in alveoli and thus may play a role in obstructive, restrictive and chronic lung 
diseases (12).  
Inhibition of LL-37 
LL-37 is a peptide that induces cytokine production via a number of 
immunocompetent and other cells, thus exhibiting immunomodulatory activity. After 
stimulation with LL-37, macrophages produce TNF-α, while mast cells release various 
interleukins (IL-2, IL-4 and IL-6). As the sole representative of the cathelicidin family of 
antimicrobial peptides in humans with immunomodulatory activity, LL-37 contributes to 
numerous autoimmune diseases, such as atherosclerosis, psoriasis, rheumatoid arthritis 
and systemic lupus erythematosus. Via the “Unbiased Target Fishing Approach”, AKBA 
binds directly to LL-37 and causes a concentration-dependent inhibition. Therefore, it is 
believed that AKBA could be a suitable natural remedy for the treatment of diseases 
related to LL-37 (17). 
Inhibition of NF-κB 
Since it controls the transcription of a large number of proinflammatory genes and 
genes related to cell proliferation, nuclear factor κB (NF-κB) is involved in the 
pathogenesis of a large number of diseases and various types of cancer. Numerous studies 
have reported that AKBA is an inhibitor of NF-κB through various mechanisms. AKBA 
binds directly to IκB-kinase (IKK) in PC-3 prostate cancer cells and LPS-stimulated 
human monocytes, consequently inhibiting the NF-κB signaling pathway and the 
induction of TNF-α. AKBA potentiates TNF-induced apoptosis, suppresses TNF-induced 
invasion, and inhibits NF-κB ligand-induced osteoclastogenesis, which is thought to 
require NF-κB activation, indicating that it may provide an effective treatment for certain 
inflammatory diseases (17). 
Clinical particulars 
Rheumatoid arthritis 
As discussed in previous section, animal and in vitro studies showed that 
frankincense extract exhibits prominent anti-inflammatory activity; therefore, it has been 
suggested as a herbal medicinal substance for potential treatment of rheumatoid arthritis 
(RA). However, the available publications bring conflicting results with regard to the 
efficiency of frankincense preparations in monotherapy or in combination products. 
Currently, there is insufficient evidence to opt either for or against the use of frankincense 
in RA treatment (12). 
In a multicentric, double-blind, placebo-controlled, 12-week pilot trial on 78 
participants with the diagnosis of rheumatoid arthritis, a smaller group of patients                           
(n = 37) was selected and treated with the standardized frankincense extract (H15® or 




(NSAIDs/corticosteroids) (12,18). In the end, only a statistically insignificant decrease in 
the use of NSAIDs was observed in the group of patients who received H15®, compared 
to placebo (5.8% vs. 3.1%). The efficacy of the tested extract was not confirmed in pain 
reduction or function improvement, as measured with validated scales. Also, no 
differences in mean values of C-reactive protein levels between groups were found (18).  
Unfortunately, the power of the test was not calculated in this trial, so it is not clear 
if the sample size was acceptable to distinguish the true treatment benefits. The methods 
of blinding and randomization were not well described, so the results of this study cannot 
be considered definitive (12). 
Etzel (1996) published a review of 11 studies conducted between 1985 and 1990, 
lasting 1-6 months and involving more than 260 patients with juvenile chronic arthritis, 
active chronic polyarthritis, or rheumatoid arthritis, who were treated with H15® (19). 
The most common study design was direct observation; placebo-controlled and double-
blind studies were also performed, but the details of each study were not provided (12). 
It was concluded that H15® improved chronic symptoms such as joint swelling and 
stiffness compared to placebo; it also reduced NSAID intake by a certain amount. As for 
the therapeutic benefits, they have been reported to be additive to other treatments, with 
minimal adverse effects. H15® is found to be a disease-modifying agent and it can replace 
other disease-modifying therapies, with unclear, but positive long-term effects on the 
joints, anatomic, and functional structures. Early use of H15® also appeared to be 
beneficial.  
Chopra et al. (2000) conducted a 16-week randomized, double-blind, placebo 
controlled parallel clinical trial of therapeutic efficacy of a combination product RA-1 in 
182 adult patients of both sexes with rheumatoid arthritis (RA) (20). RA-1 is a traditional 
formulation consisted of B. serrata, Withania somnifera (ashwagandha), Zingiber 
officinale (ginger) and Curcuma longa (turmeric) purified extracts (extraction and 
formulation details were not given), which was administered to the participants in the 
dose of 444 mg/day (2 tablets 3 times a day), with discontinuation of other RA therapies. 
Therapies by glucocorticoids and disease modifying antirheumatic drugs (DMARD) were 
ceased a month prior to enrolment, while NSAIDs were not permitted during a one-week 
washout period and throughout the whole study. Paracetamol (500 mg tablets; monitored 
use) was allowed as a “rescue analgetic” only. Signs and symptoms of RA, such as joint 
elasticity, pain, swelling, morning stiffness, etc. were assessed by ACR (American 
College of Rheumatism) core set 20% and 50% of improvement, and ACR 20% 
improvement response. Levels of C-reactive protein, rheumatoid factor (RF) and IL-6 in 
plasma were monitored as well. An intent-to-treat (ITT) analysis was performed 
(statistical tool that includes data collected from all subjects who underwent 
randomization, regardless of whether they completed the study or not); the number of 




beginning of the experiment. Seventeen patients withdrew from the study, but none due 
to adverse drug reactions or toxicity (20).  
In this trial, significant improvements were achieved in both RA-active and placebo 
groups. The RA-1 results were superior to placebo in numerical sense, but the differences 
never reached statistical significance, except for a percentage of subjects with a 50% 
reduction in swollen joints count and swollen joint score, reduction in levels of 
rheumatoid factor (30% reduction vs. 0%, respectively) and relative improvement in the 
ACR 20% assessment score (39% vs. 30%, respectively) (20).  
Although comprehensive and well-designed, this trial failed to provide stronger 
evidence of RA-1 efficacy, due to mixed statistical significance of the difference between 
the categories, which was mainly a consequence of an extraordinary and hard to explain 
placebo response, mostly coming from certain sociological factors and peculiarities of 
Indian society; therefore, the results of this trial cannot be applied to clinical practice 
(12,20). For example, rheumatoid factor, an “objective” serologic marker that is less 
affected by the “placebo effect”, significantly improved in the RA-1 group. Although 
suggestive, the results remain questionable, but certainly deserve confirmation by 
additional studies (12). 
In a double-blind, randomized, placebo-controlled, crossover trial, the efficacy of 
Articulin-F® combination product (100 mg of Boswellia serrata oleo-gum resin, 450 mg 
of Withania somnifera root, 50 mg of Curcuma longa rhizome and 50 mg of zinc complex 
per capsule) was assessed in 20 patients with RA (12,21). At a dose of 2 capsules thrice 
a day, Articulin-F® and placebo were given to the participants for 3 months. All 
medications were withdrawn 1 month prior to the study. The subjects were recruited with 
regard to signs and symptoms of RA, such as morning stiffness, swelling of joints, pain 
severity, disability or loss of function, and serologically positive rheumatoid factor. 
Assessment was based on the measurement of stiffness and pain using validated Ritchie 
articular index, American Rheumatism Association joint score and non-validated scales, 
ESR (erythrocyte sedimentation rate) and RF. The treatment with Articulin-F® led to a 
moderate improvement in all the investigated parameters (grip strength, pain, duration of 
morning stiffness, and disability score) vs. placebo; the benefits were noticed after two 
weeks of therapy and persisted by the end of the trial. After three months, conversion of 
RF to seronegativity occurred in 9 patients taking Articulin-F® and none taking placebo. 
The use of NSAIDs as rescue medicines in symptom control was necessary in 3 patients 
taking Articulin-F® versus 18 receiving placebo. The presented results are encouraging, 
although there were some issues with randomization and blinding that might introduce 
bias and confounders into the interpretation of the outcomes. Since Articulin-F® is a 





In a double blind, crossover, randomized, placebo-controlled study of 30 patients 
of either gender older than 40, with clinical and radiological diagnosis of osteoarthritis 
(OA) of the knee, the participants were given a proprietary product Cap-Wokvel® 
containing 333 mg of standardized B. serrata oleo-gum resin extract per capsule, or 
placebo (starch), thrice a day for eight weeks. After a washout period, the crossover was 
done and the patients were given the opposite of previous treatment for additional eight 
weeks. (12,22). In all patients, the intensity of swelling, severity of pain and improvement 
of function was assessed at the beginning of the study, at the end of the first phase, as 
well as at the beginning and the end of the second phase, after the crossover. All patients 
reported a decrease in pain, increase in knee flexion, increase in walking range, as well 
as better kneeling ability, sitting with crossed legs, squatting and stair climbing. However, 
although the results of this study are encouraging, there are some flaws in the 
experimental design (description randomization, blinding, and statistical analysis were 
not provided) that reduce its overall quality (12).  
Two studies of similar design (three parallel groups, two intervention groups and 
one placebo control) and undertaken by the same authors, investigated the efficacy of a 
proprietary product 5-Loxin® for a period of 12 weeks (23,24). In these studies, 
proprietary product 5-Loxin® is described as a novel B. serrata extract, containing at least 
30% of AKBA and manufactured using a selective enrichment process (Indian patent No. 
205269). The first one, by Sengupta et al. (2002) was a dose-finding study where high 
(250 mg/day) and low (100 mg/day) doses were compared (23). The most important 
finding of this study was that higher and lower doses of 5-Loxin® did not produce 
significantly distinctive outcomes.  
In a subsequent study by the same group of authors (24), the efficacy of 5-Loxin® 
(100 mg/day) was compared to Aflapin®, an alternative proprietary product containing B. 
serrata oleo-gum resin extract. Aflapin® is described in the study as a novel synergistic 
composition containing B. serrata extract selectively enriched with AKBA and B. 
serrata non-volatile oil. The non-volatile oil was prepared using a patented procedure 
(patent application PCT/IN2009/000505) involving selective removal of boswellic acids 
followed by removing volatiles under high vacuum. The composition was standardized 
to contain at least 20% AKBA (24).  
The evidence of the efficacy and safety of 5-Loxin® and Aflapin® administration in 
subjects with OA was provided. Both formulations significantly improved the function 
of joints at 100 mg/day, but Aflapin® outperformed 5-Loxin®, rapidly reducing the pain, 
after just one week of treatment. Aflapin® appeared to be capable of inhibiting cartilage 
degrading enzyme MMP-3 and to have the potential to regulate the inflammatory 





Proprietary product Articulin-F® was the subject of another complementary, 
double-blind, randomized, placebo controlled, crossover trial on 42 patients with OA 
(25), which was designed and conducted essentially the same way as previously 
described, with the same outcomes (21). At the end of the study, it was shown that the 
treatment significantly affected both the pain severity and disability scores, as assessed 
by validated instruments. On the other hand, the influence on morning stiffness, grip 
strength and joint score, although certain improvement was observed, did not reach a 
statistical significance, which could be a consequence of the sample size, which was 
inadequate for detecting true benefits. Other important flaws in the design of this study 
are unclear randomization and blinding, as well as imprecise inclusion criteria; therefore, 
the patient population may not have been homogeneous. The mixed statistical 
significance of the results and the isolated nature of this study leave open the question of 
the efficacy of Articulin-F® for OA (12). 
Bronchial asthma 
The efficacy of B. serrata oleo-gum resin was assessed in a 6-week, randomized, 
double-blind, placebo-controlled study on 80 patients with bronchial asthma, who 
received an oral dose of either 300 mg of powdered B. serrata oleo-gum resin (S-
compound®) or lactose (as placebo), thrice daily (12,26). On days 1 and 42, clinical and 
laboratory examinations were performed, and a record of asthma exacerbations was kept. 
The improvements were observed in both groups for multiple parameters. The 
improvement in spirometric parameters (forced expiratory volume during the first second 
- FEV1) was 25% in the group taking frankincense oleo-gum resin, as opposed to 5% in 
the placebo group. However, the basal mean value of FEV1 in the treatment group was 
20% lower than in the control group, so the values in both groups were near equivalent 
by the end of the study. The mean value of forced vital capacity (FVC) improved by 21% 
in the treatment group vs. 9% in the control. Secondary effects of the treatment, such as 
reduced dyspnea and eosinophilia, as well as the absence of rhonchus (a loud, wheezing 
sound heard on auscultation), were also evident in the treatment group. The number of 
asthma exacerbations was also significantly reduced in the treatment group. These results 
are in line with previous findings that constituents of frankincense are involved in the 
control of biochemical progression of asthmatic bronchoconstriction via the inhibition of 
leukotriene biosynthesis. However, a significant difference in baseline features of control 
and treatment groups was observed, raising questions about the quality of randomization 
and casting doubt on overall comparability of the groups.  
Crohn’s disease 
Gerhard et al. (2001) carried out a double-blind randomized equivalence trial using 
the standardized B. serrata oleo-gum resin extract (H15®, 1200 mg 3 times a day) or 
mesalazine (1500 mg 3 times a day) during eight weeks in 102 patients with the diagnose 




Crohn’s Disease Activity Index (CDAI), a research tool frequently used in medical 
research to quantify the multiple signs and symptoms of CD in affected patients. 
Moderate improvements in the CDAI were observed in both groups by the end of the 
study, with greater, but statistically insignificant, improvements in the group of 
participants who received H15®.  
This study was performed with numerous flaws in the design. Firstly, no power 
calculation has been performed, so it remains imprecise if the lack of significance of the 
mean scores difference between the groups was a consequence of genuine comparability 
of the two therapies, or of insufficient sample size. Also, there was no placebo group in 
the trial, so the improvements in the CDA Index in the herbal treatment group vs. baseline 
could not be distingushed from the course of the disease. Furthermore, the procedures of 
blinding and randomization were not described. Taking into account that 19 participants 
dropped out of the study (6 from the group receiving H15® and 13 from the group 
receiving mesalazine), it remained unclear if an ITT analysis was performed at all. 
Although the results of this study are promising, their clinical relevance is questionable 
due to its methodological flaws (12). 
Holtmeier et al. (2011) conducted a multicentric, 52-week, double-blind, placebo-
controlled, randomized, parallel study of efficacy of Boswelan® (3×2 soft gelatin 
capsules/day; 400 mg each) on 108 patients with CD in remission (28). Boswelan® is 
produced by extracting the B. serrata resin with 80% ethanol, mixing the obtained fluid 
extract with propylene glycol monolaurate (type I) and concentrating the mixture to yield 
an active ingredient of 400 mg native extract (28). 
The most important objective of this trial was to find out a percentage of patients 
who maintained the remission during the 52 weeks of participation. Secondary endpoints 
were time to relapse, changes of Crohn’s Disease Activity Index (CDAI), and Irritable 
Bowel Disease Questionnaire (IBDQ) scores.  
However, this trial was ceased before its planned end, because insufficient 
distinction between the scores in treatment and placebo groups was reached regarding the 
primary efficacy endpoint. Boswelan® treatment achieved slightly better results in the 
treatment group vs. the placebo, as 59.9% of actively treated patients remained in 
remission, in contrast to 55.3% in placebo group. The mean time to relapse was shorter 
in the active group than in the placebo (171 days vs. 185 days, respectively). With respect 
to CDAI, IBDQ, and laboratory tests on inflammation, no advantages were detected in 
favor of Boswelan® treatment. At the same time, no safety concerns related to Boswelan® 
administration were observed, which affirmed good tolerability of this preparation in 






In an open, non-randomized, 6-week equivalence study in patients with chronic 
colitis (n = 30, 18 - 48 years of age), the participants received either 900 mg of S 
compound® or 3 g of sulfasalazine daily, in 3 divided doses (12,29). The outcomes of 
therapy were assessed by sigmoidoscopy, rectal biopsy histopathology and stool 
examinations, as well as measurements of biochemical parameters (Hgb, Fe, Ca, P, 
plasma proteins, total leukocytes and eosinophils counts). The values obtained are 
included in the formula for determining the “remission rate”, albeit the authors omitted 
to provide details both on this formula and calculations. They found that a great majority 
of patients who received frankincense oleo-gum resin entered “remission” (18/20, or as 
much as 90%), as opposed to the sulfasalazine group (6/10, or 60%), but the difference 
in mean scores between the groups never reached statistical significance. In histological 
terms, an improvement was observed in 75% of patients receiving frankincense resin, as 
opposed to 40% in the sulfasalazine-treated group - again without statistical significance 
between the mean values of the groups. With all these limitations, it appears that the 
mentioned results cannot be interpreted clinically. The authors reported a statistically 
significant increase in “remission rate” and an improvement in histopathological findings 
in frankincense-treated group compared to baseline before therapy; however, 
comparisons with the control group were insignificant. No power of a test calculation was 
performed, so it remains blurred if the lack of significance was a consequence of real 
comparability of the two therapies, or the insufficiency of the sample size. Finally, there 
was no placebo group in the design of the experiment, so the improvements relative to 
the basal value could not be distinguished from the course of the disease. The lack of 
blinding introduced a high probability of bias into the results, and the lack of 
randomization - a chance for confounding (12). 
Collagenous colitis 
In a multicentric, placebo-controlled, randomized, double‐blind, 6-week clinical 
study on the response of patients with clinical and histological confirmation of 
collagenous colitis to administration of B. serrata oleo-gum resin extract, the participants 
(n = 31, aged 18 to 80 years), were randomly allocated to receive either the treatment 
(1200 mg of the extract daily, divided in three doses) or an equivalently formulated 
placebo. The volunteers were excluded from the study if they had received any anti-
inflammatory therapy (NSAIDs or salicylates), antibiotics and antifungal medicines 
(ketoconazole), corticosteroids or gastrokinetic agents at least 4 weeks prior to 
randomization, or if they had infectious diarrhea, earlier colon surgery, confirmed 
intolerance to frankincense constituents, or were pregnant/lactating. The primary criterion 
was clinical remission after 6 weeks (less than 3 stools per day), while the secondary 
endpoints encompassed progress in histological findings and quality of life assessment. 




clinical remission, suggesting that larger trials are necessary to determine the clinical 
efficacy of B. serrata oleo-gum resin extract in collagenous colitis (30). 
Irritable bowel syndrome 
In a supplement study by Belcaro et al., Casperome®, a new and innovative 
formulation of purified B. serrata oleo-gum resin extract, standardized to contain at least 
25% of total triterpenoid acids, with the addition of lecithin-based liposomes to enhance 
bioavailability after ingestion, was offered to healthy participants with symptoms of 
idiopathic irritable bowel syndrome (IBS) (31). Besides, the other subjects in this 
investigation have been offered to decide between the use of hyoscine butylbromide 
(Buscopan®, administered when needed) or a mixture of papaverine hydrochloride 10 mg 
and Atropa belladonna extract 10 mg (Antispasmina colica®; also administered when 
needed). The group of participants who opted for supplementation with Casperome®, 
received 1 tablet à 250 mg/day, for 4 weeks. Abdominal pain, altered movements of the 
bowel, meteorism and cramps as predominant symptoms of IBS were evaluated at 
admittance and at the end of the observational period. Also, the numbers of participants 
who needed rescue medication or medical assistance were recorded, as well as potential 
adverse events. By the end of the observation period, it was concluded that IBS symptoms 
had improved in all groups, but the number of subjects who needed medical attention or 
rescue medication significantly decreased only in Casperome® group. The administration 
of Casperome® led to a lower incidence of side effects (constipation), suggesting that it 
could be an encouraging approach to IBS salving (31).  
In a subsequent prospective, controlled, randomized clinical trial on Casperome® 
by Riva et al., 69 strictly selected healthy participants with mild IBS were assigned either 
to the standard management group (diet and Buscopan® or Antispasmina colica® if 
needed) or Casperome®-receiving group (one 250 mg tablet daily). At admittance, after 
3 and 6 months, prevalent IBS signs and symptoms (recurring and abdominal pain at 
pressure, altered movements of the bowel, flatulence and spontaneous cramps) were self-
assessed. The numbers of patients who needed rescue medication (Buscopan® 
Compositum) and who experienced any kind of adverse effects were also recorded. At 
the 6-month follow-up assessment, in the Casperome®-supplemented group, the self-
assessed values for almost all symptoms of IBS were lower in comparison to the standard 
management group, as well as the need for rescue medications and medical assistance. 
Albeit infrequent, constipation was described as the main adverse event. It was 
significantly more frequent in the group of participants who received standard medication 
(32). 
Musculoskeletal disorders 
In an open label, registry, supplement study by Franceschi et al. (2016), the safety 
and efficacy of Casperome® in the supportive management of musculoskeletal disorders 




were offered to join either a control group (standard pain management) or supplement 
group (Casperome®, 250 mg/day) and follow 4-week protocols. This registry study 
revealed that Casperome® supplementation led to an improvement in all the tested 
parameters associated with osteo-muscular pain and inflammation, as well as the need for 
rescue drugs and medical attention (33). 
Several succeeding randomized clinical trials showed that Casperome® was 
effective in a whole array of parameters that distinguish musculoskeletal disorders, like 
the overuse injury of the Achilles tendon, tennis elbow (epicondylitis), radiculopathies, 
twists of ankles and sport injuries. In all trials, a reduction of pain and improvement of 
functional capabilities of joints and adjacent tissues occurred almost promptly. Notably, 
the improvements came along with lower levels of inflammatory markers in plasma, as 
well as with a weaker need for taking rescue medication (analgetics) (34). 
Conclusions 
The reviewed articles show that B. serrata oleo-gum resin extracts exhibit 
beneficial effects that could be relevant for their use in pharmacological treatment of 
various ailments, such as rheumatoid and osteoarthritis, bronchial asthma, Crohn’s 
disease and irritable bowel syndrome, ulcerative and collagenous colitis, as well as 
various musculoskeletal disorders.  
The active constituents of B. serrata oleo-gum resin are boswellic acids (3-O-
acetyl-11-keto-β-boswellic acid, AKBA in particular), which are responsible for the 
observed anti-inflammatory activity. They obstruct the cytokine (IL-1β, IL-6 and TNF-
α) and PGE2 biosynthesis, and hinder the activities of HLE, LL-37 and transcription factor 
NF-κB. 
The available data are still insufficient to elect for the use of treatment by different 
frankincense preparations as clinically proven. Being still under-investigated, this area 
remains open for further considerations, as the clinical trials performed so far have often 
been based on erroneous research design, inadequate definition of the herbal treatment 
outcome, unclear and/or incomplete inclusion criteria for participants, or even 
manipulation of experimental data to support the expected results. 
However, it may be concluded that the knowledge on anti-inflammatory activity of 
frankincense is growing. As of this moment, it seems reasonable to predict the advent of 
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Vrste roda Boswellia (Burseraceae) su žbunovi ili nisko drveće, čiji areal rasprostranjenja 
obuhvata veliki geografski prostor između severne Afrike i Indije. Nakon zasecanja, njihova kora 
oslobađa oleogumirezinu, koja je poznata pod nazivom tamjan (Olibanum). U tradicionalnoj 
medicini, koristi se u lečenju artritisa, astme, ulcerativnog kolitisa, kašlja i ozleda. Različiti 
preparati tamjana se u prometu nalaze gotovo isključivo u obliku dodataka ishrani (dijetetskih 
suplemenata). Indijski tamjan ili Olibanum indicum je oficinalan u Evropskoj farmakopeji. 
Glavni sastojci tamjana su bosvelinske kiseline, među kojima je najznačajnija i 
najzastupljenija 3-O-acetil-11-keto-β-bosvelinska kiselina (AKBA). AKBA je inhibitor                             
5-lipoksigenaze i ispoljava antiinflamatorni i antiartritički efekat. Pored toga, tamjan sadrži 
etarsko ulje, čiji sastav u velikoj meri zavisi od biološkog izvora, kao i arabinogalaktane i 
glikoproteine. 
Malim kliničkim studijama je potvrđen izvestan pozitivan efekat raznih preparata tamjana 
na ulcerativni kolitis, bronhijalnu astmu, blage simptome sindroma iritabilnog kolona i 
poremećaje koštano-mišićnog sistema. Međutim, kod kolagenoznog kolitisa ili za održanje 
remisije Kronove bolesti, dokazi su nejasni ili izostaju. Ekstrakt bogat AKBA se pokazao 
efikasnim kod pacijenata sa osteoartritisom i, u izvesnoj meri, reumatoidnim artritisom. Skoro 
sva objavljena klinička ispitivanja su imala ozbiljne nedostatke u eksperimentalnom dizajnu, kao 
što su mala veličina uzorka i nekompletno objavljivanje eksperimentalnih podataka. Neophodne 
su veće i bolje dizajnirane studije kako bi se ostvarile preporuke za primenu u kliničkoj praksi. 
 
Ključne reči: Boswellia, tamjan, bosvelinske kiseline, antiinflamatorno delovanje.  
 
 
 
